TechnoMark News

The rising prevalence of genetic disorders owing to increasing maternal age is promoting applications of Non-Invasive Prenatal Testing (NIPT) for early detection in fetal stages. For instance, the risk of fetus having Down syndrome is about 1 in 1,250 for women who conceive at the age of 25. The risk increases to about 1 in 100 for women who conceive at the age of 40. Moreover, there are several agreements signed for the promotion of NIPT. For instance, in February 2018, Harvard Pilgrim signed a value-based contract with Illumina, Inc. to enable wider patient access to the next generation of noninvasive testing for the detection of prenatal genetic abnormalities. However, the complexities associated with Non-Invasive Prenatal Testing (NIPT) require trained professionals, which pose serious concern for growth of the market. Major Key Players of the Non-Invasive Prenatal Testing (NIPT) Market are: Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, QIAGEN, BGI, Agilent Technolo...

Non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030. The rising prevalence of genetic disorders owing to increasing maternal age is promoting applications of Non-Invasive Prenatal Testing (NIPT) for early detection in fetal stages. For instance, the risk of fetus having Down syndrome is about 1 in 1,250 for women who conceive at the age of 25. The risk increases to about 1 in 100 for women who conceive at the age of 40. Moreover, there are several agreements signed for the promotion of NIPT. For instance, in February 2018, Harvard Pilgrim signed a value-based contract with Illumina, Inc. to enable wider patient access to the next generation of noninvasive testing for the detection of prenatal genetic abnormalities. However, the complexities associated with Non-Invasive Prenatal Testing (NIPT) require trained professionals, which pose serious concern for growth of the market. Major Key P...

  Non-Invasive Prenatal Testing (NIPT) is a method to determine risks associated with certain genetic abnormalities in fetuses. Noninvasive prenatal testing (NIPT), also referred to as Non-Invasive Prenatal Screening (NIPS), involves analysis of small fragments of DNA that are circulating in a pregnant woman's blood. These fragments of DNA, called cell-free DNA (cfDNA), are obtained from the placenta and provide an opportunities for early detection of certain genetic abnormalities. The test is preferred owing to its noninvasive nature, which involves collecting a blood sample only from pregnant women without posing any risks to the fetus. NIPT is primarily performed for the identification of chromosomal disorders such as Down syndrome (also called trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome. In addition, it can also screen additional chromosomal disorders, which are caused due to missing (deleted) or copied (duplicated) sections of a...

Non-Invasive Prenatal Testing involves replacing invasive testing methods, which pose serious risks to developing fetuses. Non-Invasive Prenatal Testing (NIPT) is an emerging technology, which can be performed within 9 weeks of pregnancy and involves no risk of miscarriage. In addition, it offers clinical benefits over existing prenatal screening tests, such as maternal serum screening (MSS), by detecting the presence of trisomy 21 (Down syndrome, DS) with high sensitivity (99.9%) and specificity (98%). Moreover, there are several campaigns and programs conducted to spread awareness regarding Non-Invasive Prenatal Testing (NIPT) for the early detection of genetic abnormalities. This, in turn, contributes to growth of the Non-Invasive Prenatal Testing market. The Non-Invasive Prenatal Testing (NIPT) Market is segmented on the basis of Product Types, Method, Application and region. Major Product Types of Non-Invasive Prenatal Testing (NIPT) Market covered are: Consumables Instruments...

Non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030. The rising prevalence of genetic disorders owing to increasing maternal age is promoting applications of Non-Invasive Prenatal Testing (NIPT) for early detection in fetal stages. For instance, the risk of fetus having Down syndrome is about 1 in 1,250 for women who conceive at the age of 25. The risk increases to about 1 in 100 for women who conceive at the age of 40. Moreover, there are several agreements signed for the promotion of NIPT. For instance, in February 2018, Harvard Pilgrim signed a value-based contract with Illumina, Inc. to enable wider patient access to the next generation of noninvasive testing for the detection of prenatal genetic abnormalities. However, the complexities associated with Non-Invasive Prenatal Testing (NIPT) require trained professionals, which pose serious concern for growth of the market. Major Key P...

Non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030. The rising prevalence of genetic disorders owing to increasing maternal age is promoting applications of Non-Invasive Prenatal Testing (NIPT) for early detection in fetal stages. For instance, the risk of fetus having Down syndrome is about 1 in 1,250 for women who conceive at the age of 25. The risk increases to about 1 in 100 for women who conceive at the age of 40. Moreover, there are several agreements signed for the promotion of NIPT. For instance, in February 2018, Harvard Pilgrim signed a value-based contract with Illumina, Inc. to enable wider patient access to the next generation of noninvasive testing for the detection of prenatal genetic abnormalities. However, the complexities associated with Non-Invasive Prenatal Testing (NIPT) require trained professionals, which pose serious concern for growth of the market. Major Key P...

  Market Industry Reports (MIR) has published a new report titled “Non-Invasive Prenatal Testing (NIPT) Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the global non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030. The new study made on  Non-Invasive Prenatal Testing (NIPT) market  includes crucial information on market share, market size, and growth rate for the forecast period 2020 – 2030. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table,...

Market Industry Reports (MIR) has published a new report titled “ Non-Invasive Prenatal Testing (NIPT) Market  – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the global non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030. The rising prevalence of genetic disorders owing to increasing maternal age is promoting applications of Non-Invasive Prenatal Testing (NIPT) for early detection in fetal stages. For instance, the risk of the fetus having Down syndrome is about 1 in 1,250 for women who conceive at the age of 25. The risk increases to about 1 in 100 for women who conceive at the age of 40. Moreover, there are several agreements signed for the promotion of NIPT. For instance, in February 2018, Harvard Pilgrim signed a value-based contract with Illumina, Inc. to enable wider patient access to the next generation of nonin...

Non-Invasive Prenatal Testing (NIPT) is a method to determine risks associated with certain genetic abnormalities in fetuses. Noninvasive prenatal testing (NIPT), also referred to as Non-Invasive Prenatal Screening (NIPS), involves an analysis of small fragments of DNA that are circulating in a pregnant woman's blood. These fragments of DNA, called cell-free DNA (cfDNA), are obtained from the placenta and provide opportunities for early detection of certain genetic abnormalities. The test is preferred owing to its noninvasive nature, which involves collecting a blood sample only from pregnant women without posing any risks to the fetus. NIPT is primarily performed for the identification of chromosomal disorders such as Down syndrome (also called trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome. In addition, it can also screen additional chromosomal disorders, which are caused due to missing (deleted) or copied (duplicated) sections of a ...

Non-Invasive Prenatal Testing (NIPT) is a method to determine risks associated with certain genetic abnormalities in fetuses. Noninvasive prenatal testing (NIPT), also referred to as Non-Invasive Prenatal Screening (NIPS), involves analysis of small fragments of DNA that are circulating in a pregnant woman’s blood. These fragments of DNA, called cell-free DNA (cfDNA), are obtained from the placenta and provide an opportunities for early detection of certain genetic abnormalities. The test is preferred owing to its noninvasive nature, which involves collecting a blood sample only from pregnant women without posing any risks to the fetus. NIPT is primarily performed for the identification of chromosomal disorders such as Down syndrome (also called trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome. In addition, it can also screen additional chromosomal disorders, which are caused due to missing (deleted) or copied (duplicated) sections of a chr...